CY1105507T1 - Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες - Google Patents
Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινεςInfo
- Publication number
- CY1105507T1 CY1105507T1 CY20061100930T CY061100930T CY1105507T1 CY 1105507 T1 CY1105507 T1 CY 1105507T1 CY 20061100930 T CY20061100930 T CY 20061100930T CY 061100930 T CY061100930 T CY 061100930T CY 1105507 T1 CY1105507 T1 CY 1105507T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- compounds
- diseases
- schizophrenia
- parkinson
- Prior art date
Links
- 150000008634 thiazolopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 208000002333 Asphyxia Neonatorum Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028921 Neonatal anoxia Diseases 0.000 abstract 1
- 206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
- 206010050081 Neonatal hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 208000033300 perinatal asphyxia Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αφορά υποκατεστημένες πυραζολοπυριμιδίνες της γενικής χημικής δομής (I Α) και (I Β), μεθόδους για την παρασκευή τους, φάρμακα, τα οποία περιέχουν τις ενώσεις αυτές, τη χρησιμοποίηση των ενώσεων αυτών για την παρασκευή φαρμάκων για τη θεραπεία πόνου, επιληψίας, σχιζοφρένειας, νευρο-εκφυλιστικών ασθενειών, ειδικότερα νόσου Alzheimer, νόσου Huntington και νόσου Parkinson, εγκεφαλικών ισχαιμιών και εμφραγμάτων, ψυχώσεων που οφείλονται σε αυξημένη στάθμη αμινοξέων, εγκεφαλικών οιδημάτων, καταστάσεων υποτροφοδοσίας του κεντρικού νευρικού συστήματος, ειδικότερα σε υποξίες, ειδικότερα υποξία νεογέννητων, και ανοξίες, άνοιας AIDS, εγκεφαλομυελίτιδας, του συνδρόμου Tourette, της ασφυξίας κατά τη γέννηση, εμβοών των αυτιών, νευροπαθητικού πόνου, ασθενειών των αναπνευστικών οδών, καρκίνου, καρδιακών αρρυθμιών, ανοσο-διαταραχών και -ασθενειών, νόσου Parkinson, νεφρικής ανεπάρκειας, σχιζοφρένειας, διαταραχών ύπνου, αποπληξίας, θρομβώσεων, ακράτειας ούρων, διαβήτη, ψωρίασης, σηπτικού σοκ, εγκεφαλικών τραυμάτων, γλαυκώματος και/ή ανεπάρκειας λόγω στάσης του αίματος καθώς και φαρμακευτικά σκευάσματα που περιέχουν τις ενώσεις αυτές.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001112197 DE10112197A1 (de) | 2001-03-14 | 2001-03-14 | Substituierte Pyrazolo- und Thiazolopyrimidine |
DE2001153344 DE10153344A1 (de) | 2001-10-29 | 2001-10-29 | Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren |
PCT/EP2002/002722 WO2002072585A2 (de) | 2001-03-14 | 2002-03-13 | Substituierte pyrazolo- und thiazolopyrimidine als analgetika |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105507T1 true CY1105507T1 (el) | 2010-04-28 |
Family
ID=26008763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100930T CY1105507T1 (el) | 2001-03-14 | 2006-07-05 | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες |
Country Status (25)
Country | Link |
---|---|
US (1) | US7135568B2 (el) |
EP (2) | EP1368355B1 (el) |
JP (1) | JP2004527508A (el) |
KR (1) | KR20030082982A (el) |
CN (1) | CN1318422C (el) |
AT (2) | ATE328886T1 (el) |
AU (1) | AU2002302419B2 (el) |
BR (1) | BR0208244A (el) |
CA (1) | CA2440760C (el) |
CY (1) | CY1105507T1 (el) |
CZ (1) | CZ20032474A3 (el) |
DE (2) | DE50207103D1 (el) |
DK (1) | DK1368355T3 (el) |
ES (2) | ES2311920T3 (el) |
HK (1) | HK1061034A1 (el) |
HU (1) | HUP0401211A3 (el) |
IL (2) | IL157895A0 (el) |
MX (1) | MXPA03008291A (el) |
NO (1) | NO20034031L (el) |
NZ (2) | NZ528639A (el) |
PL (1) | PL364388A1 (el) |
PT (1) | PT1368355E (el) |
RU (1) | RU2003129060A (el) |
SK (1) | SK11542003A3 (el) |
WO (1) | WO2002072585A2 (el) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0313880B8 (pt) * | 2002-08-26 | 2021-05-25 | Takeda Pharmaceuticals Co | composto |
AU2004215644B2 (en) * | 2003-02-27 | 2010-09-02 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
US20080287405A1 (en) * | 2004-05-14 | 2008-11-20 | Thannickal Victor J | Compositions and Methods Relating to Protein Kinase Inhibitors |
AR050188A1 (es) * | 2004-08-03 | 2006-10-04 | Uriach Y Compania S A J | Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen |
EP1736475A1 (en) * | 2005-06-21 | 2006-12-27 | Ferrer Internacional, S.A. | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates |
KR100838692B1 (ko) | 2007-07-11 | 2008-06-16 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-a]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물 |
WO2009093210A2 (ru) * | 2008-01-24 | 2009-07-30 | Alla Chem, Llc | ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
EP2248816B1 (en) * | 2008-01-24 | 2014-10-22 | Alla Chem, LLC. | 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF |
EP3020719B1 (en) * | 2008-10-06 | 2017-09-20 | Alla Chem, LLC. | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof and methods for the production and use thereof |
TW201035103A (en) * | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
CN102775412B (zh) * | 2012-08-21 | 2013-05-01 | 四川大学 | 一种镇静催眠的化合物及其制备方法和用途 |
CN102977106B (zh) * | 2012-12-12 | 2014-12-10 | 中国药科大学 | 一类具有外周镇痛作用的κ阿片受体激动剂 |
CN105188694B (zh) * | 2013-03-15 | 2018-07-31 | 卓莫赛尔公司 | 用于治疗疼痛的钠通道调节剂 |
SG11201601367QA (en) * | 2013-09-10 | 2016-03-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
WO2018199235A1 (ja) * | 2017-04-27 | 2018-11-01 | 武田薬品工業株式会社 | 複素環化合物 |
CN113354644B (zh) * | 2020-03-04 | 2023-07-04 | 烟台药物研究所 | 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264773A1 (en) | 1986-10-16 | 1988-04-27 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines |
US4847256A (en) * | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
NZ233641A (en) * | 1989-05-16 | 1992-07-28 | Merrell Dow Pharma | Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions |
GB9206266D0 (en) * | 1992-03-23 | 1992-05-06 | Merck Sharp & Dohme | Therapeutic agents |
FR2717812B1 (fr) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant. |
FR2722786B1 (fr) * | 1994-07-20 | 1996-08-23 | Rhone Poulenc Rorer Sa | Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant |
DE4444815A1 (de) * | 1994-12-15 | 1996-06-20 | Merck Patent Gmbh | Thienopyridone |
JP2003288537A (ja) | 2000-09-25 | 2003-10-10 | Everyd.Com:Kk | 商品宅配システムおよび方法 |
DE10112197A1 (de) | 2001-03-14 | 2002-09-19 | Gruenenthal Gmbh | Substituierte Pyrazolo- und Thiazolopyrimidine |
-
2002
- 2002-03-13 EP EP02729998A patent/EP1368355B1/de not_active Expired - Lifetime
- 2002-03-13 MX MXPA03008291A patent/MXPA03008291A/es active IP Right Grant
- 2002-03-13 DE DE50207103T patent/DE50207103D1/de not_active Expired - Lifetime
- 2002-03-13 PT PT02729998T patent/PT1368355E/pt unknown
- 2002-03-13 CN CNB028096886A patent/CN1318422C/zh not_active Expired - Fee Related
- 2002-03-13 SK SK1154-2003A patent/SK11542003A3/sk unknown
- 2002-03-13 DE DE50212652T patent/DE50212652D1/de not_active Expired - Lifetime
- 2002-03-13 CA CA2440760A patent/CA2440760C/en not_active Expired - Fee Related
- 2002-03-13 IL IL15789502A patent/IL157895A0/xx unknown
- 2002-03-13 EP EP05026811A patent/EP1637533B1/de not_active Expired - Lifetime
- 2002-03-13 PL PL02364388A patent/PL364388A1/xx not_active Application Discontinuation
- 2002-03-13 ES ES05026811T patent/ES2311920T3/es not_active Expired - Lifetime
- 2002-03-13 WO PCT/EP2002/002722 patent/WO2002072585A2/de active IP Right Grant
- 2002-03-13 NZ NZ528639A patent/NZ528639A/en unknown
- 2002-03-13 AT AT02729998T patent/ATE328886T1/de not_active IP Right Cessation
- 2002-03-13 AU AU2002302419A patent/AU2002302419B2/en not_active Ceased
- 2002-03-13 NZ NZ540574A patent/NZ540574A/en unknown
- 2002-03-13 AT AT05026811T patent/ATE404568T1/de not_active IP Right Cessation
- 2002-03-13 KR KR10-2003-7011953A patent/KR20030082982A/ko not_active Application Discontinuation
- 2002-03-13 ES ES02729998T patent/ES2263779T3/es not_active Expired - Lifetime
- 2002-03-13 CZ CZ20032474A patent/CZ20032474A3/cs unknown
- 2002-03-13 HU HU0401211A patent/HUP0401211A3/hu unknown
- 2002-03-13 RU RU2003129060/04A patent/RU2003129060A/ru not_active Application Discontinuation
- 2002-03-13 JP JP2002571501A patent/JP2004527508A/ja active Pending
- 2002-03-13 BR BR0208244-6A patent/BR0208244A/pt not_active Application Discontinuation
- 2002-03-13 DK DK02729998T patent/DK1368355T3/da active
-
2003
- 2003-09-11 NO NO20034031A patent/NO20034031L/no not_active Application Discontinuation
- 2003-09-11 IL IL157895A patent/IL157895A/en not_active IP Right Cessation
- 2003-09-12 US US10/660,794 patent/US7135568B2/en not_active Expired - Fee Related
-
2004
- 2004-06-09 HK HK04104154A patent/HK1061034A1/xx not_active IP Right Cessation
-
2006
- 2006-07-05 CY CY20061100930T patent/CY1105507T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
IL176689A0 (en) | Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer's disease | |
DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
EA200701175A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний | |
BR0010498A (pt) | Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos | |
IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
MXPA04011612A (es) | Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo. | |
HK1074046A1 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
BRPI0410029B8 (pt) | composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto | |
BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
RU2008141076A (ru) | Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами | |
BR0207272A (pt) | Método de tratamento de doenças ou condições de desmielinação | |
ZA912652B (en) | Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation | |
DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
NO892152D0 (no) | Kondenserte diazepinoner, fremstilling derav og legemidler som inneholder dem. | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
Smeraski | Clonazepam treatment of multi-infarct dementia | |
RU97104062A (ru) | Применение селегилина для лечения эпилептических заболеваний | |
SE0004455D0 (sv) | Method for neuron regeneration in the central nervous system | |
DE69428797D1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
RU2005130403A (ru) | Средство для лечения или предотвращения заболеваний, связанных с пониженным метаболизмом костной ткани | |
王小马 et al. | THE EFFECT OF ACUPUNCTURE IN 90 CASES OF SEQUELAE OF BRAIN CONCUSSION |